Amber Salzman, Epic Bio CEO

Kite en­lists Epic Bio to ap­ply epi­ge­net­ic edit­ing in cre­at­ing next-gen CAR-T cells

Kite, the Gilead sub­sidiary spe­cial­iz­ing in CAR-T, is try­ing out epi­ge­net­ic edit­ing as it seeks new ways to cre­ate next-gen­er­a­tion cell ther­a­pies that are more ef­fec­tive against can­cer.

Team­ing up with Cal­i­for­nia-based Epic Bio, Kite will tap its new part­ner’s tech­nol­o­gy to en­gi­neer T cells by tin­ker­ing with gene ex­pres­sion — in hopes of “in essence, over­com­ing more than one tu­mor chal­lenge with one tech­nol­o­gy,” said David Bar­rett, Kite’s vice pres­i­dent of cell bi­ol­o­gy and trans­la­tion­al med­i­cine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.